GlassScriptPhysician profile
Anil Ananthaneni
NPI 1154932994
$3,255.03
in general payments reported to CMS, 2019-2025
34 companies · $1,645 in 2025
The $1,645 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $567 · 2024: $1,044 · 2025: $1,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414 · Education: $417 · Long Term Medical Supply Or Device Loan: $299 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.98 |
| Education | $416.95 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $539.66 | 2024-2025 | |
| Glaxosmithkline, LLC. | $374.21 | 2023-2025 | Jemperli, Zejula |
| Daiichi Sankyo INC. | $362.40 | 2023-2025 | Enhertu, Injectafer |
| Abbvie INC. | $266.30 | 2024-2025 | |
| Lilly USA, LLC | $143.26 | 2024 | Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $142.51 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $139.05 | 2023-2025 | Vyloy, Xtandi, Padcev |
| Acrotech Biopharma INC. | $136.73 | 2024 | Beleodaq |
| Alexion Pharmaceuticals, INC. | $115.03 | 2024-2025 | Soliris, Ultomiris |
| Astrazeneca Pharmaceuticals LP | $104.94 | 2025 | Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $88.47 | 2023-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $82.78 | 2024-2025 | |
| Pfizer INC. | $65.83 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $64.99 | 2023 | Imbruvica |
| Eisai INC. | $62.01 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $59.03 | 2023-2025 | |
| Beone Medicines USA, INC. | $55.94 | 2025 | Tevimbra, Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $49.78 | 2025 | Iclusig, Ninlaro |
| Recordati_rare_diseases_inc. | $46.79 | 2024-2025 | Sylvant |
| Incyte Corporation | $43.14 | 2025 | Zynyz, Monjuvi |
| Genentech USA, INC. | $37.99 | 2024 | Venclexta, Alecensa, Tecentriq |
| Tersera Therapeutics LLC | $34.13 | 2025 | Xermelo |
| Regeneron Healthcare Solutions, INC. | $28.99 | 2025 | Libtayo |
| Seagen INC. | $27.48 | 2023 | Adcetris |
| Exelixis INC. | $24.01 | 2024 | Cabometyx |
| Geron Corporation | $21.42 | 2025 | Rytelo |
| Tempus Ai, INC | $19.62 | 2025 | Xt Cdx |
| Celgene Corporation | $19.59 | 2023 | Reblozyl |
| Janssen Biotech, INC. | $18.02 | 2024 | Darzalex, Talvey, Tecvayli |
| Aveo Pharmaceuticals, INC. | $18.00 | 2023 | Fotivda |
| Genmab U.S., INC. | $17.53 | 2023 | Tivdak |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.26 | 2025 | |
| Pharmacosmos Therapeutics INC. | $14.35 | 2025 | Monoferric |
| Sobi, INC | $13.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Ananthaneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.